Hyperion DeFi, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Hyperion DeFi, Inc. (Nasdaq: HYPD) operates as a pioneering publicly listed company focused on building a strategic treasury reserve of Hyperliquid's native token, HYPE, while advancing ophthalmic delivery technology; it provides simplified access to the Hyperliquid ecosystem through DeFi strategies including staking, liquid staking via iHYPE and HiHYPE tokens, the HAUS (HYPE Asset Use Service) platform for fee generation, co-branded validators, and on-chain yield opportunities such as lending and liquidity provisioning on the HyperEVM. The company offers the proprietary Optejet User Filled Device (UFD), a topical ophthalmic medication dispensing platform designed for chronic front-of-the-eye diseases, artificial tears, and lens rewetting products; it features precise microdosing of 7-10 microliters per spray, horizontal delivery without head tilting, enhanced tolerability, and 98% first-attempt success rate versus traditional eye drops. Founded in 2014 and headquartered in Laguna Hills, California, Hyperion DeFi, formerly Eyenovia, Inc., conducts operations primarily in the United States with license agreements for MicroPine, MicroLine, and Mydcombi products including partnerships with Bausch Health Ireland Limited for the U.S. and Canada, and Arctic Vision and Senju Pharmaceutical for Asia; it targets institutional and retail participants in decentralized finance alongside ophthalmic patients and providers. Recent developments include a $50 million private placement in June 2025 to fund HYPE acquisitions, amassing over 1.5 million HYPE tokens; the appointment of Hyunsu Jung as Chief Investment Officer in 2025; launch of the HAUS platform with inaugural transactions alongside Credo in September 2025 for reduced trading fees and Felix in October 2025 for market launch fees; first institutional deposit into Kinetiq's iHYPE liquid staking protocol and a co-branded validator; a name change to Hyperion DeFi, Inc. on July 1, 2025; Fourth Amendment to its loan agreement with Avenue Capital extending maturity to 2028 and reducing interest rates; record Q3 2025 net income of $6.6 million driven by HYPE strategies; and anticipated FDA registration of the Optejet UFD in September 2025.
Hyperion DeFi Enters Agreement with Skew Technologies to Launch HIP-3 Perpetual Futures Market and Listing Service
Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure
Hyperion DeFi Reiterates Guidance on Sunset of USDH and Felix Markets
Hyperion DeFi, Inc. (HYPD) Q1 2026 Earnings Call Transcript
Hyperion DeFi Reports 1Q 2026 Financial Results with Record Net Income and Raises Guidance for Full Year 2026
Hyperion DeFi Announces Closing of Public Offering of Common Stock
Hyperion DeFi Announces Pricing of Public Offering of Common Stock
Hyperion DeFi Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Hyperion DeFi Schedules First Quarter Earnings Call for Thursday, May 14 at 8:00 a.m. ET
Hyperion DeFi Announces Participation in Upcoming Investor and Industry Conferences
Hyperion DeFi (NASDAQ:HYPD) versus Neuren Pharmaceuticals (OTCMKTS:NURPF) Critical Survey
Hyperion DeFi, Inc. (HYPD) Q4 2025 Earnings Call Transcript
Hyperion DeFi Reports 4Q and FY 2025 Financial Results with Quarter-over-Quarter Growth of +64% Revenue and +87% Adjusted Gross Profit
Hyperion DeFi, Inc. (NASDAQ:HYPD) Receives Consensus Recommendation of “Hold” from Analysts
Hyperion DeFi Announces Private Lending Pool Built by HyperLend
Zelira Therapeutics (OTCMKTS:ZLDAF) and Hyperion DeFi (NASDAQ:HYPD) Critical Analysis
Faron Pharmaceuticals Oy (OTC:FPHAF) & Hyperion DeFi (NASDAQ:HYPD) Financial Contrast
Hyperion DeFi, Inc. (NASDAQ:HYPD) Receives Average Rating of “Hold” from Analysts
Hyperion DeFi (NASDAQ:HYPD) CFO David Knox Acquires 27,950 Shares of Stock
Hyperion DeFi, Inc. (HYPD) Q3 2025 Earnings Call Transcript